RADNOR, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is Augus ...

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and failure to disclose critical information during designated class periods [1]. Company Summaries Hims & Hers Health, Inc. (NYSE: HIMS) - Class Period: April 29, 2025 – June 23, 2025 - Lead Plaintiff Deadline: August 25, 2025 - Allegations include deceptive promotion of illegitimate versions of Wegovy, risking patient safety, and potential termination of collaboration with Novo Nordisk, leading to materially misleading statements about the company's business and prospects [2]. iRobot Corporation (NASDAQ: IRBT) - Class Period: January 29, 2024 – March 11, 2025 - Lead Plaintiff Deadline: September 5, 2025 - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition, raising doubts about its ability to operate profitably as a standalone entity, resulting in misleading statements regarding its business and operations [3]. Centene Corporation (NYSE: CNC) - Class Period: December 12, 2024 – June 30, 2025 - Lead Plaintiff Deadline: September 8, 2025 - Allegations indicate that a preliminary analysis revealed lower-than-expected enrollment and increased market morbidity, leading to misleading statements about the company's business and prospects [4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit includes claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains the active ingredient semaglutide [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. - Following Novo Nordisk's termination of the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that negatively impacted investors between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations - The lawsuit claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2] - It is alleged that this misconduct posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing substantial settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns during the specified class period [1][3]. Group 1: Legal Proceedings - The lawsuits were filed in the United States District Court for the Northern District of California on behalf of investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1]. - The deadline for lead plaintiffs to be appointed is August 25, 2025 [1][4]. Group 2: Allegations Against Hims & Hers - Defendants are accused of failing to disclose that Hims & Hers was involved in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - There is a substantial risk that Hims & Hers' collaboration with Novo Nordisk could be terminated due to these practices [3]. - The positive statements made by the defendants regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [3]. Group 3: Investor Information - Investors who suffered losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP for more information and to potentially participate in the class action [5]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects were misleading and lacked a reasonable basis due to the aforementioned issues [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of misleading investors regarding its GLP-1 drug offerings and deceptive marketing practices, particularly in relation to its collaboration with Novo Nordisk [1][7][9]. Group 1: Legal Actions and Investigations - Securities class action lawsuits were filed against Hims & Hers and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1][3]. - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][11]. - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3]. Group 2: Events Leading to Lawsuits - Hims & Hers began offering GLP-1 treatments in May 2024, initially through compounded semaglutide, and later with FDA-approved injectable semaglutide [4]. - The FDA resolved a semaglutide product shortage on February 21, 2025, which limited Hims & Hers' ability to sell compounded semaglutide [5]. - Following assurances from management about regulatory compliance during a Q4 earnings call, Hims & Hers announced a collaboration with Novo Nordisk on April 29, 2025, which initially boosted share prices [6]. Group 3: Allegations and Marketing Practices - The lawsuits allege that Hims & Hers provided misleading assurances about its regulatory compliance and revenue from GLP-1 offerings, failing to disclose critical business practices [7]. - Plaintiffs claim that Hims & Hers engaged in deceptive marketing of unauthorized versions of Wegovy®, exposing patients to unknown risks [8]. - Novo Nordisk terminated its collaboration with Hims & Hers on June 23, 2025, citing violations of U.S. regulations regarding the sale of compounded drugs [9][10]. Group 4: Market Impact - The announcement of Novo Nordisk's termination of the partnership led to a 30% drop in Hims & Hers' share price [10].

Core Insights - Hims & Hers Health, Inc. (HIMS) has seen a significant stock increase of 90.4% over the past three months, outperforming the industry average of 13.9% and the S&P 500's growth of 18.6% [1][10] - The company is expanding into Canada and has recently acquired ZAVA, a digital health platform in Europe, marking important milestones for international growth [2][16] Financial Performance - In Q1 2025, Hims & Hers reported strong improvements in both top and bottom lines, with an increase in subscribers and monthly online revenue per average subscriber, although wholesale revenues were disappointing [3] - The company expects Q2 2025 revenues to be between $530 million and $550 million, reflecting a year-over-year increase of 68-74%, and full-year revenues projected between $2.3 billion and $2.4 billion, representing growth of 56-63% from 2024 levels [9][11] Business Strategy - Hims & Hers is focusing on weight loss treatment as a core growth area, having introduced compounded injectable semaglutide and branded semaglutide to meet high consumer demand for GLP-1 therapies [12] - The company operates a flexible subscription model that drives predictable revenue and customer retention, offering a range of health specialties including sexual health, dermatology, mental health, and weight loss [13] International Expansion - The planned expansion into Canada aims to provide affordable weight loss programs, coinciding with the anticipated availability of generic semaglutide, which is expected to be priced significantly lower than branded versions [15] - Hims & Hers is also set to introduce personalized digital health services in Europe, ensuring localized experiences with access to healthcare providers in local languages [17] Challenges - The termination of collaboration with Novo Nordisk raises concerns about future performance, as it affects access to Wegovy and highlights potential legal compliance issues [18] - A contraction in gross margin by 886 basis points in Q1 2025 due to rising product costs poses a challenge for the company if cost control measures are not implemented [19] Valuation and Market Position - HIMS' forward 12-month price-to-sales (P/S) ratio of 4.4X is lower than the industry average of 5.7X but higher than its five-year median of 2.3X, indicating potential for growth [21] - The Zacks Consensus Estimate for earnings per share for 2025 has increased to 74 cents, reflecting positive sentiment around the company's financial outlook [24]

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements from the company about its business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders are encouraged to register for the class action by the deadline of August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Class actions have been initiated for investors of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed risks related to their business operations and products [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing its collaboration with Novo Nordisk [2][3]. - Defendants are accused of making materially misleading statements regarding the safety and availability of Wegovy for Hims subscribers, which lacked a reasonable basis [2][3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, also with a lead plaintiff deadline of August 25, 2025 [4]. - Sarepta is alleged to have misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Significant safety risks associated with ELEVIDYS were not disclosed, leading to adverse events that prompted the company to halt clinical trials and attract regulatory scrutiny [4][5]. - Following reports of patient deaths related to ELEVIDYS, Sarepta's stock experienced significant declines, including a drop of $27.81 per share (27.44%) on March 18, 2025, and a further decline of $15.24 per share (42.12%) on June 15, 2025 [5][6].